Preview of ASH 2019: Key Expert-Selected Studies
  • CME

December 7-10, 2019; Orlando, Florida
Experts highlight key data to help you learn what to expect at the upcoming Hematology meeting in Orlando. The CCO Conference Coverage program will feature downloadable slides and expert commentaries of clinically relevant studies presented at ASH 2019. We will have the information you need to understand and integrate the latest hematology data into your practice.
Hanny Al-Samkari, MD
John M. Burke, MD
Elias Jabbour, MD
Rami S. Komrokji, MD
Shaji Kumar, MD
Sagar Lonial, MD
Raajit K. Rampal, MD, PhD
Jeff P. Sharman, MD
Sujit Sheth, MD
Eunice S. Wang, MD
Physicians: maximum of 1.0 AMA PRA Category 1 Credit
Released: December 5, 2019 Expiration: December 4, 2020

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Apply recently presented data to clinical practice to expand treatment options and improve outcomes for patients with hematologic malignancies and disorders
  • Discuss new data on novel agents and therapeutic approaches for patients with hematologic malignancies and disorders
  • Consider emerging clinical data on novel agents and therapeutic strategies that have the potential to improve the outcomes for patients with hematologic malignancies and disorders
Provided by the Annenberg Center for Health Sciences at Eisenhower in partnership with Clinical Care Options.
ACHS Logo

Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Dr
Dinah Shore Bldg.
Rancho Mirage, CA 92270

Melissa Velasquez, Accreditation Specialist
(760) 773-4506
(760) 773-4550 (Fax)
ce@annenberg.net
http://www.annenberg.net/

Supported by educational grants from
AstraZeneca
Celgene Corporation
Dova Pharmaceuticals, Inc.
Karyopharm Therapeutics
Loxo Oncology, Inc. a wholly owned subsidiary of Eli Lilly and Company
Pharmacyclics LLC, an AbbVie Company
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Information on this Educational Activity

The Annenberg Center assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by the Annenberg Center for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. The Annenberg Center is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Faculty

Hanny Al-Samkari, MD

Instructor
Department of Medicine
Harvard Medical School
Attending Hematologist and Clinical Investigator
Department of Hematology/Oncoology
Massachusetts General Hospital
Boston, Massachusetts

Hanny Al-Samkari, MD, has disclosed that he has received funds for research support from Agios, Amgen, and Dova and consulting fees from Agios, Dova, and Moderna.
John M. Burke, MD

Associate Chair
US Oncology Hematology Research Program
Rocky Mountain Cancer Centers
Aurora, Colorado

John M. Burke, MD, has disclosed that he has received consulting fees from AbbVie, AstraZeneca, Bayer, Celgene, Genentech, Gilead Sciences, Seattle Genetics, and Tempus and fees for non-CME/CE services from Seattle Genetics.
Elias Jabbour, MD

Associate Professor
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, Texas

Elias J. Jabbour, MD, has disclosed that he has received funds for research support from AbbVie, Adaptive, Amgen, Bristol-Myers Squibb, Novartis, Pfizer, Spectrum, and Takeda.
Rami S. Komrokji, MD

Senior Member, Vice Chair
Malignant Hematology
Section Head
Leukemia and MDS
H. Lee Moffitt Cancer Center & Research Institute
Professor
Department of Oncologic Sciences
University of South Florida
Tampa, Florida

Rami S. Komrokji, MD, has disclosed that he has received consulting fees from Celgene, Daiichi Sankyo, Jazz, Novartis, and Pfizer.
Shaji Kumar, MD

Department of Hematology
Mayo Clinic
Rochester, Minnesota

Shaji Kumar, MD, has disclosed that he has disclosed that he has received consulting fees paid to his institution from AbbVie, Amgen, Celgene, Genentech, Janssen, Kite, MedImmune, Merck, and Takeda and funds for research support from AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Janssen, Kite, MedImmune, Merck, Novartis, Roche/Genentech, Sanofi, and Takeda.
Sagar Lonial, MD

Professor and Chair
Department of Hematology and Medical Oncology
Chief Medical Officer
Winship Cancer Institute of Emory University
Atlanta, Georgia

Sagar Lonial, MD, has disclosed that he has received consulting fees from AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Celgene, GlaxoSmithKline, Janssen, Juno, Merck, Novartis, and Takeda and funds for research support from AstraZeneca, Celgene, and Takeda.
Raajit K. Rampal, MD, PhD

Assistant Member
Assistant Attending Physician
Leukemia Service
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Raajit K. Rampal, MD, PhD, has disclosed that he has received consulting fees from Beyond Spring, Celgene, Constellation, Jazz, Partner Therapeutics, and Stemline and funds for research support from Constellation and Stemline.
Jeff P. Sharman, MD

Medical Director
Hematology Research
US Oncology Research
Eugene, Oregon

Jeff P. Sharman, MD, has disclosed that he has received consulting fees from AbbVie, Acerta, AstraZeneca, BeiGene, Genentech, Gilead Sciences, Pharmacyclics, and Sunesis.
Sujit Sheth, MD

Professor
Department of Pediatrics
Weill Cornell Medicine
New York, New York

Sujit Sheth, MD, has disclosed that he has received consulting fees from Acceleron and Celgene and funds for research support from ApoPharma, Celgene, CRISPR/Vertex, La Jolla, Novartis, and Terumo.
Eunice S. Wang, MD

Professor, Oncology
Chief, Leukemia Service
Department of Medicine
Roswell Park Comprehensive Cancer Center
Buffalo, New York

Eunice Wang, MD, has disclosed that she has received consulting fees from AbbVie, Agios, Amgen, Astellas, Celyad, Daiichi Sankyo, Jazz, Kite, Pfizer, and Stemline and honoraria from Pfizer and Stemline.

Staff

Bing-e Xu, PhD

Scientific Director

Bing-E Xu, PhD, has no relevant conflicts of interest to report.
Rachael M. Andrie, PhD

Scientific Director

Rachael Andrie, PhD, has no relevant conflicts of interest to report.
Terrence Fagan

Associate Scientific Director

Terry Fagan has no relevant conflicts of interest to report.
Kristen Rosenthal, PhD

Senior Scientific Director

Kristen Rosenthal, PhD, has no relevant conflicts of interest to report.
Ryan P. Topping, PhD

Scientific Director

Ryan Topping, PhD, has no relevant conflicts of interest to report.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no relevant conflicts of interest to report.
Krista Marcello

Associate Director, Educational Strategy

Krista Marcello has no relevant conflicts of interest to report.
Jim Mortimer

Senior Director, Oncology Programs and Partnership Development

Jim Mortimer has disclosed that his spouse has received salary/ownership interest from AstraZeneca.
June Wasserstrom

Director, CME Program Development

June Wasserstrom has no relevant conflicts of interest to report.
Tina B. Stacy, PharmD, FACEHP, BCOP, CHCP

Executive Vice President, Educational Strategy
General Manager, Oncology

Tina B. Stacy, PharmD, FACEHP, BCOP, CHCP, has no relevant conflicts of interest to report.

The PIM planners and managers have nothing to disclose.

Charles E. Willis, Director of Continuing Education; Amanda Sewell, MBA, Manager of Continuing Education and Melissa Velasquez, Accreditation Specialist from the Annenberg Center for Health Sciences at Eisenhower have no relevant commercial relationships to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Annenberg Center, Postgraduate Institute for Medicine (PIM), Clinical Care Options, and activity supporters do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the Annenberg Center, PIM, Clinical Care Options, and activity supporters. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for physicians and other healthcare providers who care for patients with hematologic malignancies and disorders.

Goal

The goal of this activity is to improve learners’ understanding of how to optimally apply recent practice-changing findings in the treatment of patients with hematologic malignancies and disorders.

Physician Continuing Medical Education

Accreditation Statement

The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

The Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from December 05, 2019, through December 04, 2020:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 100% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Provided by the Annenberg Center for Health Sciences at Eisenhower in partnership with Clinical Care Options.
ACHS Logo

Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Dr
Dinah Shore Bldg.
Rancho Mirage, CA 92270

Melissa Velasquez, Accreditation Specialist
(760) 773-4506
(760) 773-4550 (Fax)
ce@annenberg.net
http://www.annenberg.net/

Supported by educational grants from
AstraZeneca
Celgene Corporation
Dova Pharmaceuticals, Inc.
Karyopharm Therapeutics
Loxo Oncology, Inc. a wholly owned subsidiary of Eli Lilly and Company
Pharmacyclics LLC, an AbbVie Company
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Related Content

Living slideset on optimal management of CLL during the COVID-19 pandemic will be continually up-to-date as the situation evolves and new data emerge

Jacqueline Barrientos, MD, MS Nicole Lamanna, MD John Pagel Headshot John Pagel, MD, PhD person default Jacob D. Soumerai, MD Released: July 2, 2020

Gain key clinical insights quickly with this short slideset from CCO on CAR T-cell therapy for hematologic malignancies.

Michael R. Bishop, MD Daniel J. DeAngelo, MD, PhD Noopur Raje, MD Released: June 30, 2020

From Clinical Care Options (CCO), read an expert commentary on ibrutinib plus rituximab for frontline CLL treatment

Anthony Mato, MD Released: June 26, 2020

In this slideset from Clinical Care Options, Jeremy S. Abramson, MD, MMSc and Christopher R. Flowers, MD, MS highlight key data on the optimal use of BTK inhibitors

Jeremy S. Abramson, MD, MMSc Christopher R. Flowers, MD, MS Released: June 26, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?